北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2025 年第二次临时股东大会的 法律意见 京天股字（2025）第 638 号 致：美年大健康产业控股股份有限公司 美年大健康产业控股股份有限公司（以下简称"公司"）2025 年第二次临时股 东大会（以下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开， 现场会议于 2025 年 10 月 14 日 14:50 在上海市静安区灵石路 697 号健康智谷 9 号 楼公司会议室召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指 派本所律师参加本次股东大会现场会议，并根据《中华人民共和国公司法》、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）以及《美年大健康产业控股股份有限公司章程》（以下 简称"《公司章程》"）等有关规定，就本次股东大会的召集、召开程序、出席会议 人员的资格、召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《美年大健康产业控股股份有限公司第九 届董事会第十三次（临时）会议决议公告》《美年大健康产业控股股份有限公 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector's potential for a reversal in 2025, particularly focusing on innovative drugs and the recovery of left-side sectors as the biggest investment opportunities for the year [5][14]. Core Insights - The innovative drug sector is expected to continue its upward trend, with BD (business development) activities anticipated to catalyze market movements. The upcoming ESMO conference (October 17-21) is highlighted as a key event for clinical data disclosures from domestic innovative drug companies [2][13]. - The report emphasizes the importance of recent Nobel Prize discoveries related to peripheral immune tolerance, which are relevant to the development of new therapies in oncology and autoimmune diseases. This underscores the significance of innovation in these fields [40][50]. - The report notes that the CXO industry in China is entering a recovery phase, with improvements expected in industry orders, capacity utilization, and performance metrics due to enhanced domestic investment and financing data [2][5]. Summary by Sections Innovative Drugs - The innovative drug sector has seen a recent pullback, but the long-term upward trend remains intact. The report suggests that the market is awaiting further BD catalysts and highlights the importance of upcoming clinical data from the ESMO conference [2][13]. - The report indicates that the overall sentiment in the innovative drug sector is still positive, with a focus on potential breakthroughs in cancer and autoimmune therapies following the recent Nobel Prize discoveries [40][50]. Biologics - Novo Nordisk announced an agreement to acquire Akero for $4.7 billion, with Akero's FGF21 analog EFX showing promise as a leading therapy for metabolic dysfunction-related fatty liver disease (MASH) [3][51]. - The report suggests that EFX is the only drug in Phase 2 trials demonstrating significant fibrosis regression in F4 patients, highlighting the need for continued attention to developments in this area [51][57]. Medical Devices - The commercialization of innovative products is accelerating, with domestic replacements making significant progress. For instance, MicroPort's Tumi laparoscopic surgical robot has surpassed 100 global orders and is leading the domestic market share [4][58]. - The report notes that the Tumi robot has received market access in over 60 countries and regions, with a strong presence in high-end markets such as Europe [60][62]. Traditional Chinese Medicine - There has been a continuous increase in new drug IND and NDA applications for traditional Chinese medicine, with 92 new IND applications and 42 NDA applications reported in the first nine months of 2025 [3][64]. - The report highlights ongoing policy support for traditional Chinese medicine, which is expected to drive further innovation and development in this sector [64][65].

Group 1 - The company, Meinian Health Industry Holdings Co., Ltd., will hold its second extraordinary general meeting of shareholders in 2025 on October 14, 2025, at 14:50 in Shanghai [2][4] - The meeting will combine on-site voting and online voting, with specific time slots for each voting method [5][6][7] - The record date for shareholders to attend the meeting is October 9, 2025 [8] Group 2 - The meeting will be convened by the company's board of directors, and the convening process complies with relevant laws and regulations [3] - Shareholders can appoint proxies to attend the meeting, and the proxies do not need to be shareholders of the company [10] - The meeting will discuss proposals that have been approved by the board of directors, with specific voting requirements for special resolutions [11] Group 3 - The company has provided guarantees for its subsidiaries, with a total guarantee limit of up to RMB 4.9 billion for the year 2025 [29] - Recent guarantees include a maximum liability of RMB 100 million for Meinian Health Industry (Group) Co., Ltd. and RMB 10 million for Chengdu Jinjiang Meinian Health [30][31] - The company has signed various guarantee contracts with banks, including Jiangsu Bank, Nanjing Bank, and others, with specific amounts and terms outlined [55][59][62] Group 4 - As of October 9, 2025, the total external guarantee balance provided by the company and its subsidiaries is RMB 36.97 billion, accounting for 46.72% of the company's audited net assets for 2024 [66] - There have been no overdue guarantees or legal disputes related to the guarantees provided by the company [66]

Group 1 - The company, Meinian Health Industry Holdings Co., Ltd., will hold its second extraordinary general meeting of shareholders in 2025 on October 14, 2025, at 14:50 in Shanghai [2][4][10] - The meeting will combine on-site voting and online voting, with the online voting period set from 9:15 to 15:00 on the same day [5][6][7] - The record date for shareholders to attend the meeting is October 9, 2025 [8] Group 2 - The meeting will review proposals that have been approved by the company's board of directors during a meeting held on September 26, 2025 [11] - Proposals will be counted separately for small and medium investors, and certain proposals require a two-thirds majority to pass [12] Group 3 - The company has provided guarantees for its subsidiaries, with a total guarantee limit of up to RMB 4.9 billion for the year 2025 [27] - Recent agreements include a guarantee of RMB 100 million for Meinian Health Industry (Group) Co., Ltd. and various other guarantees ranging from RMB 600,000 to RMB 10 million for different subsidiaries [28][29][51][62] Group 4 - As of October 9, 2025, the total external guarantee balance provided by the company and its subsidiaries is RMB 3.696 billion, accounting for 46.72% of the company's audited net assets for 2024 [64]

证券代码：002044 证券简称：美年健康 公告编号：2025-071 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2024 年 12 月 13 日召开第九届董事会第五次（临时）会议及 2024 年 12 月 30 日召开 2024 年第六次临时股东大会，审议通过《关于公司及下属子公司申请融资额度并提供 担保的议案》，同意公司及部分下属子公司 2025 年度为公司及合并报表范围内的 子公司提供担保额度累计不超过人民币 49 亿元；同意公司向成都中小企业融资担 保有限责任公司（以下简称"成都中小担保"）提供的连带责任保证提供反担保。 具体内容详见公司于 2024 年 12 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露 的《关于公司及下属子公司申请融资额度并提供担保的公告》（公告编号：2024-111）。 二、进展情况 公司与北京银行股份有限公司潍坊分行（以下简称"北京银行"）签署了 ...

美年大健康产业控股股份有限公司 证券代码：002044 证券简称：美年健康 公告编号：2025-070 关于召开 2025 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 美年大健康产业控股股份有限公司（以下简称"公司"）2025 年第二次临时 股东大会现场会议的召开地点为上海市静安区灵石路697号健康智谷9号楼三楼 公司会议室，敬请投资者特别留意。 根据公司于 2025 年 9 月 26 日召开的第九届董事会第十三次（临时）会议， 定于 2025 年 10 月 14 日召开公司 2025 年第二次临时股东大会，本次股东大会将 采用股东现场记名投票与网络投票表决相结合的方式召开，《关于召开 2025 年 第二次临时股东大会的通知》（公告编号：2025-069）已于 2025 年 9 月 27 日披 露在《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资 讯网（www.cninfo.com.cn）。现就本次股东大会的有关事宜发布提示性公告如下： 一、本次会议召开基本情况 1、股东大会届次：公司 202 ...

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

Group 1 - The company held its 13th temporary meeting of the 9th Board of Directors on September 26, 2025, with all 9 directors present, complying with relevant regulations [2][3] - The Board approved the proposal to amend the Articles of Association, which requires further approval from the shareholders' meeting with a two-thirds majority [3][4] - The Board also approved the revision and new establishment of corporate governance-related systems to enhance operational standards and compliance with laws and regulations [5][7] Group 2 - The company announced the convening of the 2025 Second Temporary Shareholders' Meeting, scheduled for October 14, 2025, with both on-site and online voting options available [11][12] - The meeting will discuss the proposals that were previously approved by the Board, requiring a two-thirds majority from attending shareholders for approval [20][21] - The company has outlined the registration process for shareholders wishing to attend the meeting, including necessary documentation and deadlines [22][24]

美年大健康产业控股股份有限公司 董事会审计委员会议事规则 第一章 总则 第一条 为强化董事会决策功能，实现对美年大健康产业控股股份有限公司 （以下简称"公司"）财务收支和各项经营活动的有效监督，公司特设董事会审 计委员会（以下简称"审计委员会"或"委员会"），作为负责公司内、外部的审 计、监督和核查工作的专门机构。 第二条 为确保审计委员会规范、高效地开展工作，公司董事会根据《中华 人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号— —主板上市公司规范运作》等法律、法规和规范性文件及《美年大健康产业控 股股份有限公司章程》（以下简称"《公司章程》"）的有关规定，特制订本议 事规则。 第三条 审计委员会所作决议，必须遵守《公司章程》、本议事规则及有关 法律、法规的规定；审计委员会决议内容违反《公司章程》、本议事规则及有 关法律、法规的规定，该项决议无效；审计委员会决策程序违反《公司章程》、 本议事规则及有关法律、法规的，自该决议做出之日起 60 日内，有关利害关系 人可向公司董事会提出撤销该项决议。 第四条 审计委员会 ...

美年大健康产业控股股份有限公司 募集资金管理办法 第一章 总则 第一条 美年大健康产业控股股份有限公司（以下简称"公司"）为规范公司 募集资金管理，提高募集资金使用效率，根据《中华人民共和国公司法》《中华 人民共和国证券法》《首次公开发行股票注册管理办法》《上市公司证券发行注 册管理办法》《上市公司募集资金监管规则》《深圳证券交易所股票上市规则》 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》 （以下简称"《规范运作》"）等法律、法规、规章及《美年大健康产业控股股份 有限公司章程》（以下简称"《公司章程》"），制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，不包括上市公司为实施股权激励 计划募集的资金。 第三条 公司董事会负责建立健全公司募集资金管理办法，并确保本办法的 有效实施。 公司的董事、高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或变相改变募集资金用途。 募集资金投资项目通过公司的子公司或公司控制的其他企业实施的，公司应 当确保该子公司或受控制的其他企业遵守本办法的各项规定。 第 ...